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The importance of iron chelation and iron availability during 
PpIX-induced photodynamic therapy
Die Bedeutung von Eisenchelation und Eisenverfügbarkeit während der PpIX-
induzierten photodynamischen Therapie
Abstract
Background: Protoporphyrin IX (PpIX)-induced photodynamic therapy (PDT) is being 
utilised as a topical method of localised ablation of certain non-melanoma skin cancers and 
precancers. Standardised protocols have been implemented to good effect when the disease 
remains superficial but improvement is required to treat thicker or acrally located conditions. 
Concurrent administration of an iron chelator during PpIX-PDT has been demonstrated to 
increase cellular accumulation of PpIX by reducing its bioconversion to haem (an iron 
dependent process) thus increasing cell kill on subsequent irradiation. Iron however, can also 
play a role in reactive oxygen species (ROS) generation and limiting its availability via 
chemical chelation which could theoretically reduce the efficacy of PpIX-PDT, so that a 
response less than that maximally feasible is produced.
Material and methods: The effects of iron availability and chelation on PpIX-PDT have 
therefore been investigated via fluorescence quantification of PpIX accumulation, single-cell 
gel electrophoresis (comet assay) measurement of ROS-induced DNA damage and trypan 
blue exclusion assessment of cell viability. Cultured human cells were utilised and incubated 
in standardised iron conditions with the PpIX precursor’s aminolaevulinic acid (ALA) or its 
methyl ester (MAL) in the presence or absence of either of the iron chelating agents 
desferrioxamine (DFO) or hydroxypyridinone (CP94), or alternatively iron sulphate as a 
source of iron.
Results: ALA or MAL incubation was found to significantly increase cellular PpIX 
accumulation pre-irradiation as anticipated and this observation correlated with both 
significantly increased DNA damage and reduced cellular viability following irradiation. Co-
incubation with either of the iron chelators investigated (DFO or CP94) significantly 
increased pre-irradiation PpIX accumulation as well as DNA damage and cell death on 
irradiation indicating the positive effect of iron chelation on the effectiveness of PpIX-
induced PDT. The opposite effects were observed however, when the cells were co-incubated 
with iron sulphate, with significant reductions in pre-irradiation PpIX accumulation (ALA 
only) and DNA damage (ALA and MAL) being recorded indicating the negative effects 
excessive iron can have on PpIX-PDT effectiveness. Some dark toxicity produced by iron 
sulphate administration in non-irradiated control groups was also observed.
Conclusion: Iron chelation and availability have therefore been observed to positively and 
adversely affect the PpIX-PDT process respectively and it is concluded that the effects of 
increased PpIX accumulation pre-irradiation produced via iron chelation outweigh any 
limitations reduced iron availability may have on the ability of iron to catalyse ROS 
generation/cascades following PpIX-induced PDT. Further investigation of iron chelation 
within dermatological applications where enhanced PpIX-PDT treatment effects would be 
beneficial is therefore warranted.
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(CP94); desferrioxamine (DFO); iron sulphate; methyl-aminolevulinate (MAL); reactive 
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Zusammenfassung
Hintergrund: Die Protoporphyrin IX (PpIX)-induzierte photodynamische Therapie (PDT) 
wird als topische Methode der lokalen Ablation von bestimmten Nicht-Melanom-
Hautkrebsarten und Präkanzerosen genutzt. Standardisierte Protokolle resultieren in einer 
guten Wirksamkeit, wenn die betroffenen Areale oberflächlich begrenzt sind, erfordern aber 
eine Verbesserung bei der Behandlung dickerer und tiefer gelegener Läsionen. Es konnte 
gezeigt werden, dass die gleichzeitige Verabreichung eines Eisenchelators während der PpIX-
PDT die zelluläre Akkumulation von PpIX verbessert, indem die biologische Umwandlung zu 
Häm (ein Eisen-abhängiger Prozess) gehemmt wird, wodurch wiederum die Zelltötung bei 
der nachfolgenden Bestrahlung erhöht wird. Eisen kann jedoch auch eine Rolle bei der 
Erzeugung von reaktiven Sauerstoffspezies (ROS) spielen und deren Verfügbarkeit durch 
chemische Chelation verringern und zumindest theoretisch die Wirksamkeit der PpIX-PDT
verschlechtern, so dass die Reaktion geringer ausfällt als die maximal mögliche Wirkung.
Material und Methoden: Es wurden die Auswirkungen der Eisenverfügbarkeit und 
Chelation auf die PpIX-PDT mittels Fluoreszenzquantifizierung der PpIX-Akkumulation, 
Einzelzell-Gelelektrophorese (Comet-Assay)-Messung der ROS-induzierten DNA-Schäden 
und Trypanblau-Ausschluss-Beurteilung der Zelllebensfähigkeit untersucht. Für die 
Experimente wurden kultivierte menschliche Zellen verwendet, die unter genormten 
Eisenbedingungen mit dem PpIX-Vorläufer Aminolävulinsäure (ALA) oder deren 
Methylester (MAL) in Gegenwart oder Abwesenheit von entweder den Eisenchelatbildnern
Deferoxamin (DFO) bzw. Hydroxypyridinon (CP94) oder alternativ Eisensulfat als 
Eisenquelle inkubiert wurden.
Ergebnisse: Wie erwartet erhöhte die Inkubation der Zellen mit ALA oder MAL vor der 
Bestrahlung die zelluläre PpIX-Anreicherung signifikant, was mit der beobachteten deutlich 
reduzierten Zelllebensfähigkeit und den verstärkten DNA-Schäden nach der Bestrahlung 
korrelierte. Eine Co-Inkubation mit einem der untersuchten Eisenchelatoren (DFO oder 
CP94) erhöhte die PpIX-Anreicherung vor der Bestrahlung ebenfalls signifikant, ebenso wie 
DNA-Schäden und Zelltod bei Bestrahlung, was den positiven Effekt der Eisenchelation auf 
die Wirksamkeit der PpIX-induzierten PDT belegt. Die entgegengesetzten Effekte wurden 
jedoch beobachtet, wenn die Zellen zusammen mit Eisensulfat inkubiert wurden. Hier zeigten 
sich eine signifikante Abnahme der PpIX-Anreicherung vor Bestrahlung (nur bei ALA) und 
verminderte DNA-Schäden (bei ALA und MAL), was die negativen Auswirkungen eines 
übermäßigen Eisengehalts auf die Wirksamkeit der PpIX-PDT belegt. Darüber hinaus wurde 
in den nicht bestrahlten Kontrollgruppen, die mit Eisensulfat inkubiert wurden, eine gewisse 
Dunkeltoxizität registriert.
Fazit: Eisenchelation und Verfügbarkeit können sowohl positiven als auch negativen Einfluss 
auf das PpIX-PDT-Verfahren haben, jedoch kann aus den Untersuchungen geschlussfolgert 
werden, dass die durch die Eisenchelation erzielte verbesserte PpIX-Anreicherung vor der 
Bestrahlung die Beschränkungen einer durch Eisen reduzierten ROS-Verfügbarkeit während 
der PpIX-induzierte PDT überwiegt. Weitere Untersuchungen der Eisenchelation innerhalb 
dermatologischer Anwendungen, wo ein verbesserter Therapieerfolg nach PpIX-PDT-
Behandlung angestrebt wird, sind daher angezeigt.
Schlüsselwörter: Aminolävulinsäure (ALA); 1,2-Diethyl-3-Hydroxypyridin-4-on 
Hydrochlorid (CP94); Deferoxamin (DFO); Eisensulfat; Methyl-Aminolaevulinat (MAL); 
reaktive Sauerstoffspezies (ROS).
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1 Introduction
Photodynamic therapy (PDT) requires three key components for a successful clinical effect –
a photosensitiser, activating light of a specific wavelength and molecular oxygen [1]. When 
combined concurrently in sufficient amounts these components result in the production of 
reactive oxygen species (ROS) and oxidative stress [2]. This process directly and indirectly 
damages cellular components leading to cell death through necrosis, apoptosis and/or 
autophagy depending on the type of photosensitiser employed, its subcellular localisation as 
well as the particular dose parameters utilised [3].
Protoporphyrin IX (PpIX)-induced PDT (PpIX-PDT) is utilised as topical method of localised 
ablation of certain non-melanoma skin cancers and precancers [4]. 5-Aminolevulinic acid 
(ALA)-induced photodynamic therapy (ALA-PDT) was first introduced experimentally by 
Malik and Lugaci in 1987 [5], with the first clinical treatments reported by Kennedy and co-
workers in 1990 [6]. Within a clinical setting topical PpIX-PDT now involves the application 
of a cream formulation containing a PpIX precursor – usually ALA or its methyl ester (MAL) 
– to the area to be treated. The area is then covered with a light-occluding dressing for a 
number of hours (usually 3 h) during which time the precursor is absorbed into the lesion and 
biochemically converted relatively rapidly by the diseased cells into the natural 
photosensitiser PpIX via haem biosynthesis. ALA or MAL applied in this way act as 
substrates for the production of haem and its precursors whilst avoiding the negative feedback 
loop that haem has on its own production. The intermediate immediately preceding haem in 
the haem biosynthesis pathway is PpIX and this accumulates following ALA or MAL 
administration because the last step of haem biosynthesis (the insertion of ferrous iron into the 
porphyrin ring of PpIX by ferrochelatase to form haem) [7] is relatively slow and is in fact the 
secondary rate limiting step of the pathway (the primary rate limiting step being the formation 
of ALA by ALA synthase which is bypassed by exogenous ALA/MAL administration). Haem 
is broken down by the enzyme haem oxygenase 1 (HO-1), a process by which iron is released. 
The level of cellular free iron is tightly controlled by homeostatic iron regulatory proteins 
which can either act by up-regulating the iron-sequestering protein ferritin or by up-regulating 
transferrin receptor synthesis [8]. These processes enable cells to respond to changes in iron 
concentration and regulate cellular labile iron levels as too little iron would adversely affect 
cell function, while too much free cellular iron could result in highly damaging metal 
catalysed ROS reactions. Iron therefore has a major and complex role in the production of 
PpIX during PpIX-induced PDT.
Once PpIX accumulation has occurred within the tumour cells in this manner, visible light 
matching both the absorption spectrum of the photosensitiser (PpIX) and the optimum
wavelength for tissue transmission is applied to the tumour; normally 635 nm is utilised for 
all but the most superficial dermatological lesions and is frequently delivered using a light-
emitting diode (LED) array [9]. PpIX absorbs energy from the light and enters a higher singlet 
energy state. This absorbed energy is then either released as fluorescence as the 
photosensitiser returns to the ground state or is transferred via intersystem crossing to the 
longer lived triplet state allowing more opportunity for energy to be transferred to nearby 
molecules in the cell. This transfer of energy from the triplet state can occur via type-I or 
type-II reactions. Type-II reactions involve the transfer of energy to oxygen to form singlet 
oxygen and this type of reaction is thought to predominate initially within the PpIX-PDT 
process [10]. Singlet oxygen can however subsequently transfer energy to other molecules 
resulting in the production of ROS cascades, which also serve to transmit damage further 
afield within the cell from the original site of initial photodynamic damage. If enough damage 
is produced within a cell, cell death can result [11] via necrosis, apoptosis and/or autophagy 
(the degradation of cellular components internally) [12–14]. Apoptosis has two major
pathways (extrinsic and intrinsic) and during PpIX-induced PDT, the intrinsic pathway is 
thought to be more important due to PpIX localisation within mitochondria [15]. Damage to 
mitochondria or loss of the mitochondrial membrane potential as can occur during PDT, may 
lead to an excessive release of ROS into the cytoplasm. These ROS, as well causing direct 
damage, may also change the redox state of the cell and initiate/modulate ROS sensitive 
signalling cascades. The damage and ROS thus produced may then induce secondary damage 
to other cellular components (including DNA).
Clinically, substantial subsets of skin tumours exist which are relatively difficult to treat with 
conventional therapies such as surgery and cryotherapy because of their size, location or 
number within an area of field change [16]. PDT can be advantageous in these situations and 
is associated with excellent cosmesis making it a particularly attractive treatment option for 
cosmetically conspicuous sites [17]. Standardised topical PpIX-PDT protocols utilising both 
ALA (Ameluz, Spirit Healthcare, UK) and MAL (Metvix, Galderma, UK) have been 
implemented within dermatology to good effect when the disease remains superficial [18], but 
improvement is required to treat thicker or acrally located conditions [19]. Many adaptations 
to standard treatment have been considered to improve efficacy including skin pre-treatment 
with the malignant cell differentiation potentiator dimethyl sulfoxide [20], skin stripping with 
tape [21], light dose fractionation [22, 23], low fluence rate light administration [24] as well 
as combinations with other techniques such as low-dose Photofrin® [25], hyperthermia [26,
27], iontophoresis [28] and bioreductive drugs [29]. Concurrent administration of an iron 
chelator, such as ethylenediamine tetraacetic acid (EDTA) [30–33], desferrioxamine (DFO) 
[30, 34–37] or the novel hydroxypyridinone iron chelator 1,2-diethyl-3-hydroxypyridin-4-one 
hydrochloride (CP94) [38–43], during PpIX-PDT has also been demonstrated to increase 
cellular accumulation of PpIX by reducing its bioconversion to haem by ferrochelatase (an 
iron dependent process) thus increasing cell kill on subsequent irradiation. This method of 
enhancement is attractive because simply increasing the precursor dose or application time 
doesn’t appear to produce cost efficacy or practical substantial improvements [44].
DFO has been demonstrated to be superior to EDTA in its ability to enhance PpIX-induced 
PDT [30] and in a separate investigation, CP94 has been found to be superior to DFO for this 
purpose [43]. CP94 is a member of the hydroxypyridinone family of oral iron chelators 
originally developed to supersede DFO in the treatment of iron overload, which has to be 
administered intravenously clinically via long infusion. CP94 is particularly effective at 
chelating intracellular iron and has a lower molecular weight and higher lipophilicity than 
either DFO or EDTA [45] and is well suited to augmenting dermatological PDT as it can be 
applied topically [46]. CP94 has already been demonstrated to enhance ALA-induced PpIX 
fluorescence [38] and to also produce greater tumour necrosis within animal models [41, 42]. 
CP94 has been investigated in a healthy skin explant model producing increased PpIX 
accumulation when employing either ALA or MAL as the PpIX precursor [39]. When the 
level of PpIX accumulation produced by DFO and CP94 were compared directly in vitro, 
these iron chelators in combination with ALA or MAL were shown to significantly increase 
the amount of PpIX accumulating within fetal lung fibroblasts (MRC-5 cells) and the more 
difficult-to-culture epidermal carcinoma cells (A431), whilst minimal enhancement was 
observed in the normal skin fibroblasts (84BR cell line) and normal human epidermal 
keratinocytes investigated. Where enhancement was observed, CP94 was consistently 
demonstrated to be significantly superior to DFO in the production of elevated PpIX levels 
[43]. Furthermore, additional studies undertaken with CP94 alone within A431 cells have 
indicated that significantly increased PpIX levels and subsequent cytotoxicity can be 
produced when using HAL (the hexyl ester of ALA) as well as ALA or MAL as the PpIX 
precursor, when PDT is conducted within a variety of different oxygen conditions [47].
Clinically Fijan et al. [35] has demonstrated the feasibility of combining the iron chelator 
DFO with ALA-PDT to treat 34 superficial basal cell carcinomas (BCCs) and 22 nodular 
BCCs with ALA. Liu et al. [32] and Choudry et al. [34] have also investigated EDTA and 
DFO respectively in humans, utilising matched skin lesion controls. Lui et al. [32] found a 
promising and significant (p<0.01) reduction in tumour depth in lesions treated with EDTA in 
combination with ALA-PDT. Choudry et al. [34] however, could not detect any significant
differences in surface fluorescence between lesions co-incubated with ALA±DFO. Two 
clinical pilot studies of CP94 in combination with ALA or MAL-induced PDT have been 
conducted to date and have demonstrated the safety and feasibility of this treatment 
modification [48, 49]. Although these clinical investigations were only designed to assess 
safety, enhancements in tumour clearance were observed both clinically and histologically 
when CP94 was included within the photosensitising cream.
However, due to its multiple valences, iron can also play an important role in ROS biology 
[50] and has the potential to increase cytotoxicity from PDT. Iron is important in the 
generation of the hydroxyl radical as well as in lipid peroxidation [51]. Singlet oxygen 
generated by PpIX-induced PDT can itself react with oxygen to generate superoxide. 
Superoxide is fairly stable under physiological conditions and does not readily react with 
other biomolecules, but its ability to generate further, more reactive ROS, makes it toxic.
Superoxide is dismutated by superoxide dismutase within cells to form hydrogen peroxide, 
which readily diffuses through membranes (due to its uncharged nature and poor reactivity). 
Hydrogen peroxide is detoxified via catalase to produce water and oxygen. However if 
hydrogen peroxide comes into contact with metal ions (especially Fe2+) then the highly 
reactive hydroxyl radical can be formed via Fenton reactions and this can lead to damage of 
cellular proteins, lipids and DNA [52]. Limiting the availability of iron via chemical chelation 
could therefore theoretically reduce the efficacy of PpIX-PDT by blocking or limiting this 
hydroxyl radical generating pathway so that a response less than that maximally feasible was 
produced by the treatment. The effects of iron availability and chelation on PpIX-PDT have 
therefore been investigated in detail here for the first time within cultured human cells 
incubated in standardised iron conditions with ALA or MAL in the presence or absence of 
either of the iron chelating agents DFO or CP94, or alternatively iron sulphate as a source of 
iron.
2 Material and methods
2.1 Cell culture
All media and disposable plastic equipment were purchased from Sigma (Poole, UK) unless 
otherwise stated. Human MRC-5 cells were obtained from the European Collection of Cell 
Cultures (ECACC, Wiltshire, UK). Cells were maintained in Eagle’s minimum essential 
medium (EMEM) supplemented with 10% iron standardised fetal calf serum (FCS), i.e. 
standardised to give an iron concentration between 450–600 µg/100 g, 2% (200 mM) L-
glutamine, 2% (200 U/ml) penicillin and (200 µg/ml) streptomycin solution. Cells were 
grown in 5% CO2 at 37°C.
It should be noted that the utilisation of FCS that consistently contained a specific amount of 
iron throughout the experimentation was an important aspect of the experimental design 
adopted for this investigation. This was important as most commercial sources of FCS contain 
varying and unspecified quantities of iron, which would not permit the effect of adding 
specific concentrations of iron sulphate to the cell cultures to be elucidated within the study 
nor in fact the effect of the iron chelator being investigated. Initial studies (data not shown) 
both with and without the presence of an iron chelating agent, also indicated that PpIX levels 
were observed to be greater without the addition of FCS to the cell culture media (i.e. without 
this source of iron being present).
2.2 Cell and solution preparation
Before conducting PpIX fluorescence measurements cell viability was assessed using trypan 
blue exclusion. Cell viability was >98% for all experimentation. Cells were seeded into the 
wells of 96-well plates (Corning, flat bottom, cell culture treated) at a density of 104 cells per 
well (i.e. 100 µl of a 105 cell/ml solution was added to each well) and incubated overnight at 
37°C in 5% CO2. At these densities cells just reached confluence after the overnight 
incubation. The following day all media were removed and the cells washed with phosphate-
buffered saline (PBS). All test solutions were freshly prepared before each experiment by 
dissolving ALA, MAL, CP94, DFO or iron sulphate into modified EMEM (minus phenol red) 
with 10% iron standardised FCS. The pH of the solutions were checked and adjusted to 
physiological pH (pH 7.4) using NaOH (0.5 M) as necessary. Solutions were then filter 
sterilised (0.22 µm, Millipore filter) before being diluted to the final concentrations utilised. 
CP94 was kindly provided as a powder by Professor Hider (King’s College London, UK).
2.3 Initial PpIX measurements
Initially an ALA or MAL concentration experiment was conducted, i.e. 0, 100 µM, 200 µM, 
300 µM, 400 µM, 500 µM and 1000 µM ALA or MAL concentrations were employed
utilising 1000 µM control groups for both congeners (Figures 1 and 2 respectively). Here, 
greater absolute levels of PpIX accumulated in the ALA-treated cells compared to the MAL-
treated cells were found. For this reason concentrations of 500 µM ALA (producing 248 a.u.
mean PpIX fluorescence in the subsequent experimentation) and 1000 µM MAL (producing 
221 a.u. mean PpIX fluorescence in the subsequent experimentation) were employed for the 
later experiments (with 500 µM ALA (Figures 3, 5 and 7) and 1000 µM MAL (Figures 4, 6 
and 8) control groups utilised respectively) so that similar levels of PpIX were generated by 
each congener at baseline (without the addition of iron or the respective iron chelators).
2.4 PpIX fluorescence assessments
During and after the addition of the test solutions all procedures were carried out under 
reduced light levels (luminance in the laboratory was reduced to 50 lx) to reduce 
photobleaching of the metabolised PpIX molecule. PpIX fluorescence was measured using a 
fluorescence plate reader (Synergy HT; BioTek, Germany). Measurements were made after an 
incubation period of 6 h with the test solutions. During this time cells were incubated in the 
dark in a 5% CO2 incubator at 37°C. A second PpIX fluorescence measurement was also 
made following light irradiation. The plate reader was pre-heated to 37°C to reduce 
temperature-edge effects. Measurements were taken with a 400 ± 30 nm excitation filter and a 
645 ± 40 nm emission filter from the bottom of the plate. The sensitivity of this system set-up 
had previously been tested in our laboratory using commercially sourced pre-synthesised 
PpIX (Sigma, UK). PpIX fluorescence was detected down to 75 pM of pre-synthesised PpIX 
[43]. PpIX was shown to be the main fluorophore detected from ALA or MAL-incubated 
MRC-5 cells by measuring the absorbance spectra of MRC-5 cells incubated with ALA or 
MAL and comparing these spectra to that of the pre-synthesised PpIX (as previously 
published [43]). Each test plate contained control cells not incubated with any of the test 
solutions. These were used to remove background fluorescence from the data sets obtained 
(blanking). Each plate also contained plate control wells containing cells incubated with 500 
or 1000 µM ALA or MAL without either iron or the iron chelating agents to give a ‘standard 
plate control’ level of PpIX production for comparison with iron chelator experimental 
groups. All PpIX fluorescence data are presented as a mean percentage ± the standard 
deviation (SD) of the PpIX production of these control cells in order to eliminate any effects 
of plate-to-plate variation on these data. A minimum of three readings were made for each 
data point presented. Statistical significance was determined using a one-way ANOVA at a 
95% confidence level.
2.5 Light irradiation
After the initial PpIX measurements had been recorded, cells were irradiated using an Aktilite 
CL128 lamp with LEDs (Galderma, Hertfordshire, UK) at a distance of 5 cm and for a period 
of 3 min. This is a commercially available LED light source that delivered 15 J/cm2 of red 
light (635±2 nm; 75 mW/cm2) to the plates. Dark control plates were also removed from the 
incubator in parallel and left in the dark on the bench for 3 min. Further fluorescence readings 
were taken from these irradiated and non-irradiated plates.
2.6 Determination of cell viability
Trypan blue exclusion was employed to determine cell viability. Following irradiation with 
the Aktilite 128 LED array (as above) plates were incubated overnight in a 5% CO2 incubator 
at 37°C. The following day the wells were washed with PBS, and 100 µl trypan blue dye was 
added to the wells. The dye was left for 3 min before being removed. The number of viable 
and non-viable adherent cells present in each well was then ascertained and the total viability 
was calculated by combining triplicate readings and presenting the data set as the mean 
percentage of the non-treated control wells (± SD).
2.7 Single cell gel electrophoresis
Confluent MRC-5 cells were incubated overnight in a 5% CO2 incubator at 37°C in T25 cm
2
tissue culture flasks with the test solutions (ALA/MAL, the iron chelators DFO or CP94, or 
alternatively iron sulphate). The following day cells were processed onto CometSlides 
(Trevigen, USA) using an alkali single cell gel electrophoresis protocol modified by Morley 
et al. [53] and originally described by Singh et al. [54]. Cells were then irradiated using the
Aktilite 128 LED array at a distance of 5 cm and for a period of 3 min (15 J/cm2; 635±2 nm; 
75 mW/cm2). Non-irradiated controls for each concentration were kept in the dark during this 
period. After irradiation, sample and corresponding dark control slides were immediately 
transferred to lysis buffer for 40 min (to minimise DNA repair), followed by transfer to 
unwinding buffer (pH>13, incubated for 40 min) and electrophoresis (24 min at 20 V, 200 
mA) according to the protocol described by Morley et al. [53]. Slides were then placed in 
100% ethanol for dehydration. Following overnight drying, slides were stained using 10 
µg/ml ethidium bromide and the DNA visualised using a fluorescence microscope (Versus;
Ceti, Antwerp, Belgium). Image analysis software (Comet Assay II; Perceptive Instruments, 
Surrey, UK) was then used to analyse 60 comets from each sample area (2 sample areas per 
slide, 240 comets scored per variable). These data were found to be non-parametric therefore 
the Mann-Whitney rank sum test was used to make statistical comparisons between the 
median values from the test and control cells. Data were presented as box-and-whisker plots 
where the median value was illustrated as a line flanked by boxes within which 25% to 75% 
of the data fell and whiskers indicating 10% to 90% of the data range observed. In a cell 
culture study Duez et al. [55] concluded that analysis of median comet data from repeated 
experiments is an efficient way to demonstrate genotoxic effects with ALA [55].
3 Results
3.1 ALA/MAL alone PpIX fluorescence: DNA damage and cell viability
Throughout all experiments similar trends were observed whether ALA or MAL was 
employed. Pre-irradiation PpIX fluorescence increased with increasing concentrations of both 
ALA (Figure 1A) and MAL (Figure 2A). Irradiation of the cells with red light (15 J/cm2) 
resulted in photobleaching of the ALA/MAL-induced PpIX and a subsequent significant drop 
(p<0.05) in the level of PpIX fluorescence observed (Figures 1A and 2A). As anticipated this 
photobleaching was not observed in the non-irradiated controls (Figures 1B and 2B).
The cellular damage (in the form of DNA damage) observed after light irradiation in the ALA 
or MAL-treated MRC-5 cells (Figures 1C and 2C respectively) increased with increasing pre-
irradiation PpIX levels and post irradiation photobleaching, with no significant DNA damage 
being measured in the non-irradiated controls (Figures 1D and 2D). No statistically significant 
increases in DNA damage were also detected following irradiation after incubation with the 
lowest doses of ALA (?? ????µM) or MAL (?? ????µM) but DNA damage increased in a 
concentration dependent manner with concentrations above 300 µM ALA and 400 µM MAL 
respectively (Figures 1C and 2C). 
At the highest concentrations of ALA investigated DNA damage was at the upper limit of that 
detectable using the comet assay (Figure 1C). The level of damage detected in the MAL-
treated cells (Figure 2C) was slightly lower than that detected with corresponding 
concentrations in the ALA-treated cells. This was reflected by the levels of PpIX detected 
with ALA and MAL, with MAL-incubated cells accumulating less PpIX than their ALA-
treated counterparts (Figures 2A and 1A respectively). In the subsequent iron and iron 
chelator experiments the concentration of ALA used was therefore lowered from 1000 µM to 
500 µM to account for the differences in PpIX accumulation between ALA and MAL and to 
reduce the level of DNA damage to a level detectable by the comet assay.
The post irradiation cell viability of the ALA or MAL-treated MRC-5 cells (Figures 1E and
2E) was inversely related to the levels of pre-irradiation PpIX fluorescence (Figures 1A and
2A) detected and DNA damage (Figures 1C and 2C). This effect was not observed within the 
non-irradiated controls where viability remained high (Figures 1F and 2F). These 
observations collectively indicated that high levels of PpIX accumulation pre-irradiation, 
followed by PpIX photobleaching and increased DNA damage post irradiation were 
associated with reduced cell viability suggesting that PpIX-PDT cytotoxicity was related to 
the oxidative damage produced on irradiation and that PpIX accumulation alone (without light 
exposure) was not genotoxic. A significant reduction in cellular viability was however 
observed in the non-irradiated 500 µM MAL-treated cells possibly denoting some slight dark 
toxicity of this compound at the higher concentrations investigated.
The fractionally reduced PpIX levels post sham irradiation in the non-irradiated controls was 
probably the result of some minor bleaching of the PpIX molecule occurring due to exposure 
of the cells to ambient light during the sham irradiation process and/or the excitation light 
from the plate reader. The non-significant nature of the bleaching observed indicated that the 
measures taken to reduce photobleaching (such as the reduction of laboratory lighting levels) 
were adequate and did not substantially adversely affect the results recorded within the 
irradiated groups. 
3.2 ALA/MAL plus DFO PpIX fluorescence: DNA damage and cell viability
Co-incubation of ALA or MAL with the iron chelating agent DFO resulted in significantly 
(p<0.05) increased levels of PpIX detected compared to that detected in ALA or MAL-only 
treated MRC-5 cells (Figures 3A and 4A respectively) however over the dose range 
investigated (50–300 µM DFO) the PpIX levels generated remained relatively consistent 
despite the variation in iron chelator dose. As observed in Figures 1 and 2, irradiation resulted 
in significant photobleaching (p<0.05) (Figures 3A and 4A) and this was not observed in the 
non-irradiated controls (Figures 3B and 4B).
The DNA damage observed in the ALA+DFO co-incubated cells following irradiation was 
consistently significantly higher than in the ALA-only treated cells (p<0.05) (Figure 3C). 
However only the 150 µM DFO+MAL-treated cells had levels of DNA damage that were 
statistically higher than the MAL-only treated cells (p<0.05) (Figure 4C). With both 
congeners no DNA damage above background levels was observed when no irradiation was 
delivered (Figures 3D and 4D).
Cell viability was significantly reduced in both ALA and MAL-treated cells following 
irradiation (p<0.05) (Figures 3E and 4E respectively). In the non-irradiated cells cell viability 
was not significantly reduced (Figures 3F and 4F) in any of the treatment groups investigated. 
These findings indicate that similar mechanistic processes of cellular damage and death 
appear to be occurring during PpIX-induced PDT with and without the iron chelator, DFO.
3.3 ALA/MAL plus CP94 PpIX fluorescence: DNA damage and cell viability
Co-incubation of both ALA and MAL with CP94 resulted in relatively consistent significant 
enhancements in the level of pre-irradiation PpIX fluorescence detected (p<0.05) (Figures 5A 
and 6A respectively). Again significant photobleaching of PpIX fluorescence was only 
observed following irradiation (Figures 5A and 6A) but not in the non-irradiated controls 
(Figures 5B and 6B). 
The subsequent DNA damage observed after light irradiation in the CP94 co-incubated cells 
(Figures 5C and 6C) was once again related to the pre-irradiation levels of PpIX with greater 
levels of PpIX fluorescence pre-irradiation being associated with greater DNA damage 
following irradiation. The DNA damage observed in these CP94 co-incubated cells was 
significantly (p<0.05) higher than in the ALA or MAL-only (0 µM CP94) treated cells at all 
CP94 concentrations investigated (Figures 5C and 6C respectively). The level of DNA 
damage detected in the non-irradiated ALA or MAL-treated cells (Figures 5D and 6D
respectively) was much lower than that detected in the irradiated cells (Figures 5C and 6C). 
This level of damage was at the expected background level of DNA damage for this cell type 
as observed in previous experimentation (data not shown).
As observed with DFO, cell viability was also reduced by the administration of CP94 in the 
irradiated cells (Figures 5E and 6E) but remained high in the non-irradiated cells (Figures 5F 
and 6F) with either ALA or MAL incubation in all cases except for the highest dose of ALA 
investigated which fell but in a non-statistically significant manner (Figure 5F). It is also 
interesting to note that within the irradiated groups the level of DNA damage produced by 
PpIX-PDT recorded with CP94 appeared a little greater than with DFO, whereas the reverse 
trend was observed with cell viability. On the whole both iron chelating agents actually 
performed in a similar manner, which is of note as being bidentate, three times the amount of 
CP94 should be required to chelate the same quantity of iron as multidentate DFO.
3.4 ALA/MAL plus iron sulphate PpIX fluorescence: DNA damage and cell viability
The mean level of PpIX fluorescence detected pre-irradiation in the ALA+iron sulphate co-
incubated cells decreased in a concentration dependent manner with increasing iron sulphate 
concentration (p<0.05) (Figure 7A). This was in sharp contrast to the opposite effect observed 
with the iron-chelated cells (ALA+DFO, Figure 3A; and ALA+CP94, Figure 5A) and 
highlights the importance of the limiting role of iron availability has on PpIX accumulation 
(by facilitating haem synthesis) and supports the hypothesis that the iron chelators 
investigated mediated their effects through sequestering iron to reduce the conversion of PpIX 
to haem resulting in elevated PpIX accumulation. Again the application of light to the cells 
resulted in significant PpIX photobleaching (p<0.05) (Figure 7A), an effect not substantially 
observed in the non-irradiated controls (Figure 7B).
On irradiation a significant concentration dependent decrease in DNA damage (p<0.05) 
occurred with increasing iron sulphate concentration (Figure 7C). This was consistent with 
the level of PpIX initially detected within the cells pre-irradiation (Figure 7A) and suggested 
that the limiting effect of iron availability on PpIX accumulation had a greater (negative) 
effect on the level of DNA damage produced than the potential (positive) role that iron may 
have had catalysing the ROS cascades that occur subsequent to PpIX-PDT. It therefore 
appears to be more beneficial to chelate iron (Figures 3, 4, 5 and 6) rather than supplement it 
(Figures 7 and 8) when trying to improve PpIX-PDT (Figures 1 and 2) treatment effects.
Interestingly in the non-irradiated iron sulphate-treated cells (10–100 µM), DNA damage 
increased significantly (p<0.05) above that observed with the 0 µM control group (Figure 7D) 
(albeit to a much smaller degree than observed in the irradiated cells; Figure 7C), reiterating 
the importance of the normal homeostatic processes of tight cellular control of iron levels to 
reduce the oxidative damage that can be catalysed by the availability of this transition metal. 
This effect of additional iron supply was also observed in the corresponding viability 
experiments (Figure 7F) but cell viability was reduced to a much greater extent following 
irradiation and appeared to be relatively consistent at all iron sulphate concentrations 
investigated (Figure 7E).
In the MAL+iron sulphate co-incubated cells there was no significant difference in the level 
of PpIX detected in the cells with increasing iron concentrations either with (Figure 8A) or 
without irradiation (Figure 8B). This suggested that the process of conversion of PpIX to 
haem was already operating at a maximal rate with this particular concentration of MAL and 
was not being limited by iron availability (therefore iron supplementation made very little 
impact on PpIX accumulation). A significant (p<0.05) reduction in DNA damage was 
however observed in the 10 µM and 100 µM iron sulphate co-incubated cells (Figure 8C). 
However this reduction in DNA damage observed with MAL (Figure 8C) had no obvious 
trend and was less pronounced than that observed in the ALA co-incubated cells (Figure 7C)
and therefore was in general agreement with the unaltered MAL-PpIX accumulation observed 
with increasing concentrations of iron sulphate in Figure 8A. Again as observed in the 
ALA+iron sulphate-treated cells, DNA damage was very slightly higher in the non-irradiated 
MAL-treated cells incubated in the presence of iron sulphate (Figure 8D). Once again cell 
viability was significantly reduced in the light irradiated MAL+iron sulphate-incubated cells 
(Figure 8E) but remained high in the non-irradiated MAL+iron sulphate-treated cells (Figure 
8F) with very little difference being observed with the varying concentrations of iron sulphate 
investigated here (which again was in agreement with the unaltered MAL-induced PpIX 
levels observed with increasing concentrations of iron sulphate in Figure 8A).
4 Discussion
These findings demonstrate the importance of the role of iron within the mechanism of PpIX-
induced PDT. The changes in damage seen with different iron levels were predominantly 
related to the accumulation of PpIX pre-irradiation, with higher levels of PpIX and 
subsequent cellular damage/death observed in the iron chelator-treated cells (Figures 3, 4, 5 
and 6). 
Less absolute PpIX fluorescence was detected in the MAL-treated cells (Figure 2) compared 
to that of the ALA-treated cells (Figure 1). It is thought that once absorbed the methyl group 
of MAL is liberated in the cell by non-specific esterases. This extra enzyme step may have 
reduced the overall rate of accumulation of PpIX in our cellular system. Alternatively 
differences in the rate of uptake by the MRC-5 cells may have accounted for this difference. 
Because of the disparity in the levels of PpIX generated by ALA and MAL in this 
investigation concentrations of 500 µM ALA and 1000 µM MAL were employed, so that 
roughly similar levels of PpIX were generated by ALA or MAL incubation without co-
incubation with the iron chelators or iron (this also meant that the subsequent levels of DNA 
damage generated were within the optimal range for detection via single cell gel 
electrophoresis).
When light was applied, significant photobleaching of the PpIX molecule was observed. This 
was as expected and similar photobleaching is observed with ALA-PDT in vivo [24]. 
Photobleaching of PpIX has previously been shown to be a good indicator of photodynamic 
effect, and is light and oxygen dependent [56]. The level of PpIX photobleaching produced by 
light irradiation in this investigation was related to the subsequent level of DNA damage 
detected.
Co-incubation with the iron chelators (Figures 3, 4, 5 and 6) resulted in significantly increased 
levels of PpIX being detected compared to the ALA/MAL-only treated control cells with 
either congener employed. This finding supports previously published work in this area [30,
38, 43], furthermore being conducted in an iron controlled/standardised environment here. 
When activated by light these higher levels of PpIX resulted in increased cellular damage (as 
measured via DNA damage). This DNA damage was light dependent and was associated with 
reduced cell viability (as determined by trypan blue exclusion). DNA damage (using the 
Comet assay) has previously been reported in normal fibroblasts exposed to ALA-PDT (using 
a single ALA dose of 1 mM) [57]. Our results support these findings and extend them to also 
consider a greater number of ALA concentrations as well as iron supplementation/chelation 
with both DFO and CP94 and the methyl ester of ALA as a PpIX precursor.
More recently Chu and co-workers [58] have reported ALA-PDT-mediated DNA damage 
measured using the Comet assay. In contrast to Haylett et al. [57], Chu et al. [58] reported that 
no significant DNA damage could be detected in nasopharyngeal carcinoma cells using the 
Comet assay (despite these cells being treated with the same concentration of ALA, 1 mM, as 
those used by Haylett et al. [57]). Chu et al. [58] however commenced the Comet assay 24 h 
after irradiation and it was previously demonstrated by Haylett et al. [57] that cells can repair 
DNA fully within this time and so in the investigation reported here, DNA damage was 
assessed immediately following irradiation. 
It should be noted that the Comet assay is a quantitative measure of strand breaks and does 
not give information on the type of damage or qualitative nature of repair. It has previously 
been reported however that ALA-PDT specifically results in an increase in 8-oxo-7,8-
dihydro-2’-deoxyguanosine (a mutagenic marker for oxidative damage) [59]. This would fit 
the current understanding of ALA-PDT-mediated DNA damage as an essentially ROS-
mediated process. Following PDT several of the enzymes involved in ROS detoxification e.g. 
manganese superoxide dismutase [60] and gamma-glutamylcysteine synthetase (the enzyme 
that catalyses the rate limiting step of glutathione synthesis) [61] have also been reported to 
have been up-regulated. DNA strand breaks can also result from apoptosis, which has also 
been observed to occur following ALA-PDT [62]. However as the Comet assay was 
performed immediately following light irradiation in this investigation, apoptosis would not 
be expected to occur in this short time period. Therefore although it is clear from the findings 
presented here that DNA damage did occur immediately following PpIX-PDT, further 
experimentation will be required to conclusively demonstrate that this was the result of 
oxidative stress and no other process. 
However it is known that iron can also play an important role in ROS biology and has the 
potential to increase cytotoxicity from PDT. This has been previously demonstrated in vitro
where cells were incubated with iron either before or after light irradiation [64]. Iron-before-
light irradiation resulted in less PpIX accumulating from the ALA pro-drug employed and a 
subsequent drop in lethality (as also observed here). Adding iron after irradiation increased 
lethality [63] and this aspect was not considered by the present study as such a manipulation 
would not be clinically practical.
The purpose of the investigation reported here was to further understand the effect of iron 
chelation and iron availability on the overall level of PpIX accumulation and cell 
damage/death detected during PpIX-PDT. The association between PpIX accumulation and 
cellular damage (in the form of DNA damage) and cell viability was the focus, rather than any 
repair that may occur as the result of any (sub-lethal) cellular damage produced by the 
treatment protocols employed or likewise the mode of cell death induced. Although DNA 
damage immediately following irradiation was observed there is no suggestion that this would 
be persistent or mutagenic in nature (although this possibility is theoretically feasible). 
Additionally as therapeutic PpIX-PDT treatments are designed to be cytotoxic, any DNA-
damaged cells would not be expected to survive the treatment and new carcinogenesis within
treatment fields has not been reported clinically during follow-up periods following licensed 
dermatological PpIX-PDT applications [64]. It is therefore very interesting to note that the 
significant increases in DNA damage observed here with ALA and MAL (Figures 1C and 2C
respectively) started t??????????????????????????????????????????????????????????? the 
corresponding cellular cytotoxicity was observed to be reaching approximately 50% (Figures 
1E and 2E respectively). Our findings have suggested that the role of limited iron levels in 
elevating PpIX accumulation has a greater effect on the level of cellular damage produced by 
PpIX-induced PDT than the role of excess iron availability in the formation of ROS (as the 
level of damage/death was related to the differences in the accumulation of PpIX observed). A 
possible explanation for this may be that other transition metals (such as zinc or copper) may 
have mediated Fenton-type reactions instead of iron in the ROS cascades triggered by PpIX-
PDT. Having free iron available may have therefore not been crucial for this purpose and it is 
also likely that iron-mediated Fenton reactions are only a small part of a much larger 
mechanism of damage mediated by PpIX-induced PDT which is known to be originally 
initiated by type-II singlet oxygen production [65]. Furthermore, although cellular iron levels 
are tightly regulated under normal circumstances, during oxidative stress iron homeostasis can 
be disrupted resulting in the release of labile iron [66–68]. This may also partially explain our 
findings, so that iron chelation initially reduces iron availability so that PpIX accumulation 
during PpIX-PDT is elevated and once a state of oxidative stress begins to occur on 
irradiation other transition metals and freshly released labile iron perpetuate the ROS cascades 
via Fenton reactions. This hypothesis will however require further experimentation to 
conclusively ascertain.
Interestingly where pre-synthesised PpIX has been administered to cells, it has previously 
been demonstrated [63] that the addition of iron can increase cell kill (the opposite effect to 
that observed here). In this scenario however, iron-mediated ROS reactions would be much 
more important as the iron applied would not affect the level of PpIX located within the 
mitochondria of the cell but instead is thought to catalyse the reduction of lipid 
hydroperoxides resulting in free radial lipid peroxidation of the cell membrane.
This current study therefore highlights the important role of iron in the formation of cellular 
damage/death in ALA and MAL-PDT both with (Figures 3, 4, 5 and 6) and without the 
presence of an iron chelator (Figures 1 and 2). The enhancements in PpIX fluorescence 
detected in the DFO and CP94 co-incubated cells were translated into greater cellular DNA 
damage and subsequently greater cell death, presumably through the iron chelators’ ability to 
limit free iron in the cellular system thus inhibiting the final step of haem biosynthesis, 
resulting in the higher levels of PpIX observed in these experiments pre-irradiation. 
Conversely co-incubation of iron with ALA/MAL-treated cells (Figures 7 and 8) resulted in 
lower PpIX pre-irradiation levels being detected, and subsequently following irradiation, 
lower levels of cellular damage and increased cell viability being observed.
5 Conclusion
In conclusion, iron chelation and availability during PpIX-PDT has been demonstrated to be 
an important aspect of this complex biochemical treatment process and the effects of 
increased PpIX accumulation pre-irradiation produced via iron chelation appear to be more 
crucial than having free iron available to catalyse the oxidative PpIX-PDT induced ROS 
cascades that ensue. Furthermore, the ability of the iron chelating agents investigated here 
(DFO and CP94) to increase the accumulation of pre-irradiation PpIX levels during 
ALA/MAL-induced PDT, enabled greater levels of cellular DNA damage and cell death to be 
generated upon irradiation. Additional investigations into the clinical application of 
concomitant iron chelation during PpIX-PDT (particularly with topically available iron 
chelating compound, CP94) would therefore be beneficial in order to determine whether a 
more effective treatment protocol could be derived in this manner for dermatological 
applications that currently require some improvement in efficacy.
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Figure legends
Figure 1 Results observed with MRC-5 cells incubated with various concentrations (0 to 
1000 µM) of ALA for 6 h. Mean (± SD) PpIX fluorescence before (solid line) and after 
irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm light delivery. Box-and-
whisker plots of median DNA damage with (C) or without (D) irradiation. Mean (± SD) 
trypan blue cell viability with (E) or without (F) irradiation.
Figure 2 Results observed with MRC-5 cells incubated with various concentrations (0 to 
1000 µM) of MAL for 6 h. Mean (± SD) PpIX fluorescence before (solid line) and after 
irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm light delivery. Box-and-
whisker plots of median DNA damage with (C) or without (D) irradiation. Mean (± SD) 
trypan blue cell viability with (E) or without (F) irradiation.
Figure 3 Results observed with MRC-5 cells incubated with 500 µM ALA plus 
increasing concentrations of DFO (0 to 300 µM) for 6 h. Mean (± SD) PpIX fluorescence 
before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm 
light delivery. Box-and-whisker plots of median DNA damage with (C) or without (D) 
irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) irradiation.
Figure 4 Results observed with MRC-5 cells incubated with 1000 µM MAL plus 
increasing concentrations of DFO (0 to 300 µM) for 6 h. Mean (± SD) PpIX fluorescence 
before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm 
light delivery. Box-and-whisker plots of median DNA damage with (C) or without (D) 
irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) irradiation.
Figure 5 Results observed with MRC-5 cells incubated with 500 µM ALA plus 
increasing concentrations of CP94 (0 to 300 µM) for 6 h. Mean (± SD) PpIX fluorescence 
before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm 
light delivery. Box-and-whisker plots of median DNA damage with (C) or without (D) 
irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) irradiation.
Figure 6 Results observed with MRC-5 cells incubated with 1000 µM MAL plus 
increasing concentrations of CP94 (0 to 300 µM) for 6 h. Mean (± SD) PpIX fluorescence 
before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 J/cm2 635 nm 
light delivery. Box-and-whisker plots of median DNA damage with (C) or without (D) 
irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) irradiation.
Figure 7 Results observed with MRC-5 cells incubated with 500 µM ALA plus 
increasing concentrations of iron sulphate (0 to 100 mM) for 6 h. Mean (± SD) PpIX 
fluorescence before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 
J/cm2 635 nm light delivery. Box-and-whisker plots of median DNA damage with (C) or 
without (D) irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) 
irradiation.
Figure 8 Results observed with MRC-5 cells incubated with 1000 µM MAL plus 
increasing concentrations of iron sulphate (0 to 100 µM) for 6 h. Mean (± SD) PpIX 
fluorescence before (solid line) and after irradiation (dashed line) with (A) or without (B) 15 
J/cm2 635 nm light delivery. Box-and-whisker plots of median DNA damage with (C) or 
without (D) irradiation. Mean (± SD) trypan blue cell viability with (E) or without (F) 
irradiation.
